Publications by authors named "G Hamet"
Pancreatic cancer in people with HIV: a case-control study.
J Acquir Immune Defic Syndr
December 2024
Background: We aimed to estimate the incidence and to assess the risks factors associated with pancreatic cancer (PC) in people with HIV (PWH).
Setting: We used electronic medical record data from 2009 to 2020 available in the COREVIH Ile-de-France Est database of PWH treated in Paris' public hospitals.
Methods: We analyzed data on patient demographics, treatment history, and immuno-virologic status.
In a retrospective study conducted in three hospitals in Paris, generic antiretroviral accounted for 30.2% of all prescriptions. Tenofovir disoproxil/emtricitabine (TDF/FTC) was the most prescribed generic ART (82.
View Article and Find Full Text PDFBackground: We evaluated complex pre-exposure prophylaxis (PrEP) situations linked to kidney issues in a cohort of on-demand and daily PrEP users.
Setting: We conducted a single-center retrospective cohort study in France including all PrEP users who received a tenofovir disoproxil (TD)-emtricitabine (FTC) prescription between January 1, 2012 and December 31, 2019 with at least 1 creatinine measurement available before and after PrEP initiation.
Methods: A complex kidney situation (CKS) was defined as an estimated glomerular filtration rate (eGFR) <60 mL/minute/1.
Objective: The aim of this study was to assess updated mortality and causes of death in people with HIV (PWH) in France.
Design And Methods: We analyzed all deaths in PWH followed up between January 1, 2020, and December 31, 2021, in 11 hospitals in the Paris region. We described the characteristics and causes of death among deceased PWH, and evaluated the incidence of mortality and associated risk factors using a multivariate logistic regression.
Article Synopsis
- The study evaluated the effectiveness of switching HIV patients on stable antiretroviral therapy to a co-formulated drug called E/C/F/TDF, measuring success by the number of patients maintaining low viral loads at 48 weeks.
- A total of 382 patients were analyzed, showing that 82% maintained viral loads below 50 copies/mL, while only 3.5% experienced virological failure, primarily linked to past treatment issues.
- Resistance to integrase inhibitors was noted in those who failed treatment, though overall, the switch to E/C/F/TDF was well tolerated with minimal adverse effects reported.